Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 148 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Elranatamab for treating relapsed /refractory multiple myeloma	Elranatamab (PF-06863135)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download
Emicizumab for mild or moderate haemophilia A	Emicizumab (Hemlibra)	Haemophilia A	Haematology	2021	View \| Download
Empagliflozin for Chronic Heart Failure with Preserved Ejection Fraction	Empagliflozin (Jardiance; DINAMO)	Heart failure (HF)	Cardiovascular System	2021	View \| Download
Epcoritamab for diffuse large B-cell lymphoma after two previous treatments	Epcoritamab (GEN-3013)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Erdafitinib for treating advanced solid tumours with an FGFR mutation in people aged 6 years and older	Erdafitinib (JNJ-42756493; BALVERSA)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2021	View \| Download
Estetrol for treating vasomotor symptoms	Estetrol (Donesta; E4)	Hot flushes	Women's Health	2021	View \| Download
Etrolizumab for Crohn’s Disease	Etrolizumab (PRO145223; RG7413; rhuMAb Beta7)	Crohn's disease	Gastroenterology , Immunology	2021	View \| Download
Fidanacogene elaparvovec for haemophilia B	Fidanacogene elaparvovec (SPK-9001)	Haemophilia B	Haematology	2021	View \| Download
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma	Glofitamab (RG-6026)	Diffuse large B-cell lymphoma (DLBCL) , High grade B cell lymphoma (HGBCL) , Primary mediastinal large B-cell lymphoma (PMBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line	Infigratinib (BGJ398; BGJ-398; Truseltiq)	Cholangiocarcinoma	Gastrointestinal Cancer	2021	View \| Download